ArticleVirchows Archiv : an international journal of pathology2026
Temporality of change in Ki67 labelling following neoadjuvant systemic chemotherapy of breast cancer-the common drop often subsides with time.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ki67 immunohistochemistry is widely used in clinical settings to assess tumour proliferation in breast cancer, yet the temporal changes in Ki67 labelling index following neoadjuvant chemotherapy (NACT) are underexplored. Matched core biopsy and surgical excision specimens of invasive breast cancers were collected, and the Ki67 immunostained slides were examined. Ki67 labelling index was determined and statistically evaluated based on the time elapsed between the last cycle of NACT and surgery. Subgroup analyses were carried out based on surrogate molecular subtypes, Residual Cancer Burden (RCB), and European Working Group for Breast Screening Pathology tumour regression (TR) categories. The study included 54 paired breast cancer cases post-NACT. Most tumours were RCB-II (n = 39) and TR2b (n = 20). The average time from NACT completion to surgery was 40.3 days. Of three methods (including image-analysis and sample-counting), eye-balling estimation provided the best linear regression fit (p = 0.003, R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.